about
Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthmaNuclear factor-kappaB activity is down-regulated in nasal polyps from aspirin-sensitive asthmaticsSignal transduction pathways (MAPKs, NF-κB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.Expression of the human glucocorticoid receptor alpha and beta isoforms in human respiratory epithelial cells and their regulation by dexamethasone.Lung myofibroblasts are characterized by down-regulated cyclooxygenase-2 and its main metabolite, prostaglandin E2.Expression of glucocorticoid receptors alpha and beta in steroid sensitive and steroid insensitive interstitial lung diseases.Effect of lipopolysaccharide on glucocorticoid receptor function in control nasal mucosa fibroblasts and in fibroblasts from patients with chronic rhinosinusitis with nasal polyps and asthma.Glucocorticoid receptors in human airways.Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosisAlpha and beta glucocorticoid receptors: relevance in airway diseases.Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2.Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis.EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis.Expression of glucocorticoid receptor alpha- and beta-isoforms in human cells and tissues.Cyclooxygenase-2 is up-regulated in lung parenchyma of chronic obstructive pulmonary disease and down-regulated in idiopathic pulmonary fibrosis.Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: Vicious circle in patients with aspirin-exacerbated respiratory disease.Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts.Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells.Regulation of glucocorticoid receptor in nasal polyps by systemic and intranasal glucocorticoids.Deficient glucocorticoid induction of anti-inflammatory genes in nasal polyp fibroblasts of asthmatic patients with and without aspirin intolerance.MP29-02* reduces eosinophil survival induced by epithelial cell secretions from nasal mucosa.Glucocorticoid therapy increases COX-2 gene expression in nasal polyps in vivo.Differential expression of remodeling markers by tissue structure in nasal polyposis.Low prostaglandin E2 and cyclooxygenase expression in nasal mucosa fibroblasts of aspirin-intolerant asthmatics.Effect of desloratadine on epithelial cell granulocyte-macrophage colony-stimulating factor secretion and eosinophil survival.Glucocorticoid receptor isoforms alpha and beta in in vitro cytokine-induced glucocorticoid insensitivity.United airways: the impact of chronic rhinosinusitis and nasal polyps in bronchiectasic patient's quality of life.Fluticasone furoate inhibits cytokine secretion from nasal epithelial cells and reduces eosinophil survival in an in vitro model of eosinophilic inflammation.Altered expression and signalling of EP2 receptor in nasal polyps of AERD patients: role in inflammation and remodelling.Oral plus nasal corticosteroids improve smell, nasal congestion, and inflammation in sino-nasal polyposis.Corticosteroid treatment regulates mucosal remodeling in chronic rhinosinusitis with nasal polyps.United airways again: high prevalence of rhinosinusitis and nasal polyps in bronchiectasis.Severe nasal polyposis and its impact on quality of life. The effect of a short course of oral steroids followed by long-term intranasal steroid treatment.[Cyclooxigenase-2 levels are increased in the lung tissue and bronchial tumors of patients with chronic obstructive pulmonary disease].Relevance of COX-2 gene expression in dementia with lewy bodies associated with Alzheimer pathology.Nuclear translocation of the glucocorticoid receptor in fibroblasts of asthmatic patients with nasal polyposis insensitive to glucocorticoid treatment.Effects of topical anti-inflammatory drugs on eosinophil survival primed by epithelial cells. Additive effect of glucocorticoids and nedocromil sodium.The importance of smell in patients with bronchiectasisSuperior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markersReduced expression of COXs and production of prostaglandin E2 in patients with nasal polyps with or without aspirin-intolerant asthma
P50
Q28171128-A6BE3571-EA02-4AAC-933F-7AF20177FAF6Q28195310-342941AD-523A-42AD-AD7B-8472E89D320BQ30459926-DB8CCAB7-2069-47AE-BB12-2ED5CFF99643Q31816368-A92AFDE5-60CF-4E3B-8F71-066FEAEB797CQ34766530-578D6443-A6A9-486E-A1A8-6287FCC15FEAQ35536857-2BC596E7-5E06-494F-A2DD-C0A9D79B4165Q35622585-A5D6711B-2822-4ADE-8348-5CD3DEFF6145Q35881911-4B721F1A-CED1-43B0-8D99-1E1B45F8951EQ36184104-2A7173F4-79D9-4CC4-903C-FD77A38B18E0Q36793265-65322AB9-847D-4060-B749-89547FE890DAQ37418337-E3E7134A-EF07-4DF1-9625-6656146DFF07Q38541804-DCC119C5-F0F7-4F51-8E54-49A8F8BD5BFAQ40202376-18E7BE82-FFEF-44C4-A226-7FC8D2CC9497Q40704658-3CEBE8C5-BA0B-48C0-80A2-AE75B6D23447Q42461205-5C1C4374-4724-4D9B-82A1-23ACFEA1E65BQ42484997-B6C390E6-285F-4B3E-9AE7-E14CB0205A3AQ42509474-DB01A1E1-D3DB-4C4F-AE12-C9CADA037BA7Q43630163-0514C213-66E8-4D91-81BD-147BB52BBDEFQ44906352-F06008FB-06F2-4E41-AF88-5F1DC230F313Q45747860-D934BEEF-8386-495A-BCEB-FE24C57544C3Q45895283-69B5E3FE-FEF7-462E-8D8A-762F93497FA3Q46104726-AEC9A6F6-3493-4CBE-B771-D7AE56EDEAB3Q46201333-C4DD9F93-F69F-4E47-8902-87CC83EFF6C5Q46240727-667F1F80-CDB2-45A2-8C75-CE809983CD29Q46879567-5CDC939E-A33B-4618-B550-DF68869FC9CBQ47378060-F9D95824-C280-46AA-9FE0-F8646C2402EBQ49022576-A4A84B3A-D298-4C38-8157-DE60D464AB9EQ50224777-26C96690-9457-4C20-A507-D5D344339A3DQ50271674-143DBF05-7672-4F95-B706-210D3DE55F5CQ50487856-BF9FBA74-B7E4-4B88-8C05-9CD496A28CB4Q51662443-D4E27C34-C50C-4CB7-B13E-1A3C1435FE54Q51828968-C18864C8-50E4-4FBB-B3C1-1D4BC3579FD4Q51920077-32895344-B9D3-45F4-A758-ACB9D753E171Q53283976-4419D7D1-07C7-49BD-B053-83BD513C4791Q53391751-E4106B19-F32F-4516-81A0-BD0AFBF73D80Q53856737-9201E199-4A7C-4C8A-80F4-162923FC9361Q54149968-30F17B10-D4FB-41F2-A6B8-7F8F3584FC03Q59308454-3FEE90EE-1299-4CD3-BAE5-A84961B44A48Q60044004-784251B0-B160-4D18-848F-683DE7D20CABQ62520456-4B227A2D-4B4F-4545-B82E-9CE278F6A65C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura Pujols
@ast
Laura Pujols
@en
Laura Pujols
@es
Laura Pujols
@nl
Laura Pujols
@sl
type
label
Laura Pujols
@ast
Laura Pujols
@en
Laura Pujols
@es
Laura Pujols
@nl
Laura Pujols
@sl
prefLabel
Laura Pujols
@ast
Laura Pujols
@en
Laura Pujols
@es
Laura Pujols
@nl
Laura Pujols
@sl
P1053
G-8920-2015
P106
P21
P31
P3829
P496
0000-0003-3708-5098